1
|
Choy L, Norris S, Wu X, Kolumam G, Firestone A, Settleman J, Stokoe D. Inhibition of Aurora Kinase Induces Endogenous Retroelements to Induce a Type I/III IFN Response via RIG-I. Cancer Res Commun 2024; 4:540-555. [PMID: 38358346 PMCID: PMC10896070 DOI: 10.1158/2767-9764.crc-23-0432] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/02/2023] [Revised: 12/20/2023] [Accepted: 02/02/2024] [Indexed: 02/16/2024]
Abstract
Type I IFN signaling is a crucial component of antiviral immunity that has been linked to promoting the efficacy of some chemotherapeutic drugs. We developed a reporter system in HCT116 cells that detects activation of the endogenous IFI27 locus, an IFN target gene. We screened a library of annotated compounds in these cells and discovered Aurora kinase inhibitors (AURKi) as strong hits. Type I IFN signaling was found to be the most enriched gene signature after AURKi treatment in HCT116, and this signature was also strongly enriched in other colorectal cancer cell lines. The ability of AURKi to activate IFN in HCT116 was dependent on MAVS and RIG-I, but independent of STING, whose signaling is deficient in these cells. MAVS dependence was recapitulated in other colorectal cancer lines with STING pathway deficiency, whereas in cells with intact STING signaling, the STING pathway was required for IFN induction by AURKi. AURKis were found to induce expression of endogenous retroviruses (ERV). These ERVs were distinct from those induced by the DNA methyltransferase inhibitors (DNMTi), which can induce IFN signaling via ERV induction, suggesting a novel mechanism of action. The antitumor effect of alisertib in mice was accompanied by an induction of IFN expression in HCT116 or CT26 tumors. CT26 tumor growth inhibition by alisertib was absent in NSG mice versus wildtype (WT) mice, and tumors from WT mice with alisertib treatment showed increased in CD8+ T-cell infiltration, suggesting that antitumor efficacy of AURKi depends, at least in part, on an intact immune response. SIGNIFICANCE Some cancers deactivate STING signaling to avoid consequences of DNA damage from aberrant cell division. The surprising activation of MAVS/RIG-I signaling by AURKi might represent a vulnerability in STING signaling deficient cancers.
Collapse
Affiliation(s)
- Lisa Choy
- Calico Life Sciences LLC, South San Francisco, California
| | - Stephen Norris
- Calico Life Sciences LLC, South San Francisco, California
| | - Xiumin Wu
- Calico Life Sciences LLC, South San Francisco, California
| | - Ganesh Kolumam
- Calico Life Sciences LLC, South San Francisco, California
| | - Ari Firestone
- Calico Life Sciences LLC, South San Francisco, California
| | | | - David Stokoe
- Calico Life Sciences LLC, South San Francisco, California
| |
Collapse
|
2
|
Asundi J, Zhang C, Donnelly‐Roberts D, Solorio JZ, Challagundla M, Connelly C, Boch C, Chen J, Richter M, Maneshi MM, Swensen AM, Lebon L, Schiffmann R, Sanyal S, Sidrauski C, Kolumam G, Baruch A. GDF15 is a dynamic biomarker of the integrated stress response in the central nervous system. CNS Neurosci Ther 2024; 30:e14600. [PMID: 38357857 PMCID: PMC10867791 DOI: 10.1111/cns.14600] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2023] [Revised: 12/11/2023] [Accepted: 12/28/2023] [Indexed: 02/16/2024] Open
Abstract
AIM Characterize Growth Differentiation Factor 15 (GDF15) as a secreted biomarker of the integrated stress response (ISR) within the central nervous system (CNS). METHODS We determined GDF15 levels utilizing in vitro and in vivo neuronal systems wherein the ISR was activated. Primarily, we used the murine model of vanishing white matter disease (VWMD), a neurological disease driven by persistent ISR in the CNS, to establish a link between levels of GDF15 in the cerebrospinal fluid (CSF) and ISR gene expression signature in the CNS. GDF15 was also determined in the CSF of VWM patients. RESULTS GDF15 expression was increased concomitant to ISR activation in stress-induced primary astrocytes as well as in retinal ganglion cells following optic nerve crush, while treatment with 2Bact, a specific eIF2B activator, suppressed both the ISR and GDF15. In the VWMD model, CSF GDF15 levels corresponded with the magnitude of the ISR and were reduced by 2BAct. In VWM patients, mean CSF GDF15 was elevated >20-fold as compared to healthy controls, whereas plasma GDF15 was undifferentiated. CONCLUSIONS These data suggest that CSF GDF15 is a dynamic marker of ISR activation in the CNS and may serve as a pharmacodynamic biomarker for ISR-modulating therapies.
Collapse
Affiliation(s)
- Jyoti Asundi
- Calico Life Sciences LLCSouth San FranciscoCaliforniaUSA
| | - Chunlian Zhang
- Calico Life Sciences LLCSouth San FranciscoCaliforniaUSA
| | | | | | | | | | | | | | | | | | | | - Lauren Lebon
- Calico Life Sciences LLCSouth San FranciscoCaliforniaUSA
| | | | | | | | - Ganesh Kolumam
- Calico Life Sciences LLCSouth San FranciscoCaliforniaUSA
| | - Amos Baruch
- Calico Life Sciences LLCSouth San FranciscoCaliforniaUSA
| |
Collapse
|
3
|
Hu B, Seybold B, Yang S, Sud A, Liu Y, Barron K, Cha P, Cosino M, Karlsson E, Kite J, Kolumam G, Preciado J, Zavala-Solorio J, Zhang C, Zhang X, Voorbach M, Tovcimak AE, Ruby JG, Ross DA. 3D mouse pose from single-view video and a new dataset. Sci Rep 2023; 13:13554. [PMID: 37604955 PMCID: PMC10442417 DOI: 10.1038/s41598-023-40738-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2022] [Accepted: 08/16/2023] [Indexed: 08/23/2023] Open
Abstract
We present a method to infer the 3D pose of mice, including the limbs and feet, from monocular videos. Many human clinical conditions and their corresponding animal models result in abnormal motion, and accurately measuring 3D motion at scale offers insights into health. The 3D poses improve classification of health-related attributes over 2D representations. The inferred poses are accurate enough to estimate stride length even when the feet are mostly occluded. This method could be applied as part of a continuous monitoring system to non-invasively measure animal health, as demonstrated by its use in successfully classifying animals based on age and genotype. We introduce the Mouse Pose Analysis Dataset, the first large scale video dataset of lab mice in their home cage with ground truth keypoint and behavior labels. The dataset also contains high resolution mouse CT scans, which we use to build the shape models for 3D pose reconstruction.
Collapse
Affiliation(s)
- Bo Hu
- Google, 1600 Amphitheatre Parkway, Mountain View, CA, 94043, USA.
| | - Bryan Seybold
- Google, 1600 Amphitheatre Parkway, Mountain View, CA, 94043, USA
| | - Shan Yang
- Google, 1600 Amphitheatre Parkway, Mountain View, CA, 94043, USA
| | - Avneesh Sud
- Google, 1600 Amphitheatre Parkway, Mountain View, CA, 94043, USA
| | - Yi Liu
- Calico Life Sciences LLC, 1170 Veterans Blvd., South San Francisco, CA, 94080, USA
| | - Karla Barron
- Calico Life Sciences LLC, 1170 Veterans Blvd., South San Francisco, CA, 94080, USA
| | - Paulyn Cha
- Calico Life Sciences LLC, 1170 Veterans Blvd., South San Francisco, CA, 94080, USA
| | - Marcelo Cosino
- Calico Life Sciences LLC, 1170 Veterans Blvd., South San Francisco, CA, 94080, USA
| | - Ellie Karlsson
- Calico Life Sciences LLC, 1170 Veterans Blvd., South San Francisco, CA, 94080, USA
| | - Janessa Kite
- Calico Life Sciences LLC, 1170 Veterans Blvd., South San Francisco, CA, 94080, USA
| | - Ganesh Kolumam
- Calico Life Sciences LLC, 1170 Veterans Blvd., South San Francisco, CA, 94080, USA
| | - Joseph Preciado
- Calico Life Sciences LLC, 1170 Veterans Blvd., South San Francisco, CA, 94080, USA
| | - José Zavala-Solorio
- Calico Life Sciences LLC, 1170 Veterans Blvd., South San Francisco, CA, 94080, USA
| | - Chunlian Zhang
- Calico Life Sciences LLC, 1170 Veterans Blvd., South San Francisco, CA, 94080, USA
| | - Xiaomeng Zhang
- Translational Imaging, Neuroscience Discovery, Abbvie, 1 N. Waukegan Rd., North Chicago, IL, 60064-1802, USA
| | - Martin Voorbach
- Translational Imaging, Neuroscience Discovery, Abbvie, 1 N. Waukegan Rd., North Chicago, IL, 60064-1802, USA
| | - Ann E Tovcimak
- Translational Imaging, Neuroscience Discovery, Abbvie, 1 N. Waukegan Rd., North Chicago, IL, 60064-1802, USA
| | - J Graham Ruby
- Calico Life Sciences LLC, 1170 Veterans Blvd., South San Francisco, CA, 94080, USA
| | - David A Ross
- Google, 1600 Amphitheatre Parkway, Mountain View, CA, 94043, USA
| |
Collapse
|
4
|
Zhang J, Tsukui T, Wu X, Brito A, Trumble JM, Caraballo JC, Allen GM, Zavala-Solorio J, Zhang C, Paw J, Lim WA, Geng J, Kutskova Y, Freund A, Kolumam G, Sheppard D, Cohen RL. An immune-based tool platform for in vivo cell clearance. Life Sci Alliance 2023; 6:e202201869. [PMID: 37311583 PMCID: PMC10264967 DOI: 10.26508/lsa.202201869] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2022] [Revised: 05/30/2023] [Accepted: 05/31/2023] [Indexed: 06/15/2023] Open
Abstract
Immunological targeting of pathological cells has been successful in oncology and is expanding to other pathobiological contexts. Here, we present a flexible platform that allows labeling cells of interest with the surface-expressed model antigen ovalbumin (OVA), which can be eliminated via either antigen-specific T cells or newly developed OVA antibodies. We demonstrate that hepatocytes can be effectively targeted by either modality. In contrast, pro-fibrotic fibroblasts associated with pulmonary fibrosis are only eliminated by T cells in initial experiments, which reduced collagen deposition in a fibrosis model. This new experimental platform will facilitate development of immune-based approaches to clear potential pathological cell types in vivo.
Collapse
Affiliation(s)
| | - Tatsuya Tsukui
- Division of Pulmonary, Critical Care, Allergy and Sleep, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA
| | - Xiumin Wu
- Calico Life Sciences LLC, South San Francisco, CA, USA
| | | | | | - Juan C Caraballo
- Division of Pulmonary, Critical Care, Allergy and Sleep, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA
| | - Greg M Allen
- Department of Medicine, University of California San Francisco, San Francisco, CA, USA
| | | | | | - Jonathan Paw
- Calico Life Sciences LLC, South San Francisco, CA, USA
| | - Wendell A Lim
- Department of Medicine, University of California San Francisco, San Francisco, CA, USA
- Cell Design Institute, University of California San Francisco, San Francisco, CA, USA
| | | | | | - Adam Freund
- Calico Life Sciences LLC, South San Francisco, CA, USA
| | | | - Dean Sheppard
- Division of Pulmonary, Critical Care, Allergy and Sleep, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA
| | | |
Collapse
|
5
|
Roux AE, Zhang C, Paw J, Zavala-Solorio J, Malahias E, Vijay T, Kolumam G, Kenyon C, Kimmel JC. Diverse partial reprogramming strategies restore youthful gene expression and transiently suppress cell identity. Cell Syst 2022; 13:574-587.e11. [PMID: 35690067 DOI: 10.1016/j.cels.2022.05.002] [Citation(s) in RCA: 22] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2021] [Revised: 02/15/2022] [Accepted: 05/10/2022] [Indexed: 01/25/2023]
Abstract
Partial pluripotent reprogramming can reverse features of aging in mammalian cells, but the impact on somatic identity and the necessity of individual reprogramming factors remain unknown. Here, we used single-cell genomics to map the identity trajectory induced by partial reprogramming in multiple murine cell types and dissected the influence of each factor by screening all Yamanaka Factor subsets with pooled single-cell screens. We found that partial reprogramming restored youthful expression in adipogenic and mesenchymal stem cells but also temporarily suppressed somatic identity programs. Our pooled screens revealed that many subsets of the Yamanaka Factors both restore youthful expression and suppress somatic identity, but these effects were not tightly entangled. We also found that a multipotent reprogramming strategy inspired by amphibian regeneration restored youthful expression in myogenic cells. Our results suggest that various sets of reprogramming factors can restore youthful expression with varying degrees of somatic identity suppression. A record of this paper's Transparent Peer Review process is included in the supplemental information.
Collapse
Affiliation(s)
- Antoine E Roux
- Calico Life Sciences, LLC, 1170 Veterans Blvd, South San Francisco, CA 94080, USA
| | - Chunlian Zhang
- Calico Life Sciences, LLC, 1170 Veterans Blvd, South San Francisco, CA 94080, USA
| | - Jonathan Paw
- Calico Life Sciences, LLC, 1170 Veterans Blvd, South San Francisco, CA 94080, USA
| | - José Zavala-Solorio
- Calico Life Sciences, LLC, 1170 Veterans Blvd, South San Francisco, CA 94080, USA
| | - Evangelia Malahias
- Calico Life Sciences, LLC, 1170 Veterans Blvd, South San Francisco, CA 94080, USA
| | - Twaritha Vijay
- Calico Life Sciences, LLC, 1170 Veterans Blvd, South San Francisco, CA 94080, USA
| | - Ganesh Kolumam
- Calico Life Sciences, LLC, 1170 Veterans Blvd, South San Francisco, CA 94080, USA
| | - Cynthia Kenyon
- Calico Life Sciences, LLC, 1170 Veterans Blvd, South San Francisco, CA 94080, USA
| | - Jacob C Kimmel
- Calico Life Sciences, LLC, 1170 Veterans Blvd, South San Francisco, CA 94080, USA.
| |
Collapse
|
6
|
Martin-McNulty B, Ramachandran M, Craft W, Kolumam G. Abstract 563: Age-related Differences In Vascular Remodeling Resulting From Acute Injury. Arterioscler Thromb Vasc Biol 2022. [DOI: 10.1161/atvb.42.suppl_1.563] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/05/2022]
Abstract
Background:
The vascular system, like other organ systems, ages, leading to differences in remodeling due to injury. The hallmark of acute vascular injury is the formation of intimal hyperplasia. Vascular procedures performed in the elderly, such as angioplasty, stent and other cardiovascular procedures/surgeries, result in higher rates of acute vascular injury compared to younger adults. We explored age-related differences in vascular remodeling due to acute injury using the unilateral carotid artery ligation (CAL) murine model.
Methods:
Four-month and twenty-two-month-old C57BL/6 male mice underwent ligation of the left common carotid artery immediately received either angiotensin II (1.4 mg/kg/day; Lig+Ang II) or vehicle (phosphate-buffered saline; Lig) via subcutaneous osmotic minipumps for 4 weeks.
Results:
Compared to young murine arteries, histopathology showed increased thinning and straightening of elastin in 22 mo. old arteries, as well as increasing collagen deposition in the media layer, resulting in thicker vessel walls.Old vessels were more susceptible to insults, as observed in the Lig group. In turn, the old vessel remodeled with neo-intimal formation, fragmentation of elastin and narrowing of the lumen, whilst there was no neo-intimal formation in the young arteries under the same injury.Even though Ang II increased remodeling in the young vessels with neo-intimal formation, Ang II exacerbated remodeling in the aged arteries with enough intimal hyperplasia that led to the occlusion of the lumen with a necrotic core, and the complete disintegration of the elastin. Molecular analysis showed differences between young and old arteries with and without perturbation.
Conclusions:
Together, these results indicate that vascular ageing can be detected in old arteries, but that there are age-dependent differences in vascular remodeling following acute injury revealed through pathological and molecular analysis. Thus, this study has provided an invaluable tool for understanding the mechanisms of neo-intimal formation in restenosis to elderly patients following angioplasty and vein grafts. It is also a means for pre-clinical pharmacological interventions.
Collapse
Affiliation(s)
| | | | - Wendy Craft
- Calico Life Science, LLC, South San Francisco, CA
| | | |
Collapse
|
7
|
Chen Z, Raj A, Prateek GV, Di Francesco A, Liu J, Keyes BE, Kolumam G, Jojic V, Freund A. Automated, high-dimensional evaluation of physiological aging and resilience in outbred mice. eLife 2022; 11:e72664. [PMID: 35404230 PMCID: PMC9000950 DOI: 10.7554/elife.72664] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2021] [Accepted: 03/29/2022] [Indexed: 02/06/2023] Open
Abstract
Behavior and physiology are essential readouts in many studies but have not benefited from the high-dimensional data revolution that has transformed molecular and cellular phenotyping. To address this, we developed an approach that combines commercially available automated phenotyping hardware with a systems biology analysis pipeline to generate a high-dimensional readout of mouse behavior/physiology, as well as intuitive and health-relevant summary statistics (resilience and biological age). We used this platform to longitudinally evaluate aging in hundreds of outbred mice across an age range from 3 months to 3.4 years. In contrast to the assumption that aging can only be measured at the limits of animal ability via challenge-based tasks, we observed widespread physiological and behavioral aging starting in early life. Using network connectivity analysis, we found that organism-level resilience exhibited an accelerating decline with age that was distinct from the trajectory of individual phenotypes. We developed a method, Combined Aging and Survival Prediction of Aging Rate (CASPAR), for jointly predicting chronological age and survival time and showed that the resulting model is able to predict both variables simultaneously, a behavior that is not captured by separate age and mortality prediction models. This study provides a uniquely high-resolution view of physiological aging in mice and demonstrates that systems-level analysis of physiology provides insights not captured by individual phenotypes. The approach described here allows aging, and other processes that affect behavior and physiology, to be studied with improved throughput, resolution, and phenotypic scope.
Collapse
Affiliation(s)
- Zhenghao Chen
- Calico Life Sciences LLC, South San FranciscoSouth San FranciscoUnited States
| | - Anil Raj
- Calico Life Sciences LLC, South San FranciscoSouth San FranciscoUnited States
| | - GV Prateek
- Calico Life Sciences LLC, South San FranciscoSouth San FranciscoUnited States
| | - Andrea Di Francesco
- Calico Life Sciences LLC, South San FranciscoSouth San FranciscoUnited States
| | - Justin Liu
- Calico Life Sciences LLC, South San FranciscoSouth San FranciscoUnited States
| | - Brice E Keyes
- Calico Life Sciences LLC, South San FranciscoSouth San FranciscoUnited States
| | - Ganesh Kolumam
- Calico Life Sciences LLC, South San FranciscoSouth San FranciscoUnited States
| | - Vladimir Jojic
- Calico Life Sciences LLC, South San FranciscoSouth San FranciscoUnited States
| | - Adam Freund
- Calico Life Sciences LLC, South San FranciscoSouth San FranciscoUnited States
| |
Collapse
|
8
|
Peclat TR, Thompson KL, Warner GM, Chini CC, Tarragó M, Mazdeh DZ, Zhang C, Zavala‐Solorio J, Kolumam G, Liang Wong Y, Cohen RL, Chini EN. CD38 inhibitor 78c increases mice lifespan and healthspan in a model of chronological aging. Aging Cell 2022; 21:e13589. [PMID: 35263032 PMCID: PMC9009115 DOI: 10.1111/acel.13589] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2021] [Revised: 02/12/2022] [Accepted: 03/01/2022] [Indexed: 11/29/2022] Open
Abstract
Nicotinamide adenine dinucleotide (NAD) levels decline during aging, contributing to physical and metabolic dysfunction. The NADase CD38 plays a key role in age‐related NAD decline. Whether the inhibition of CD38 increases lifespan is not known. Here, we show that the CD38 inhibitor 78c increases lifespan and healthspan of naturally aged mice. In addition to a 10% increase in median survival, 78c improved exercise performance, endurance, and metabolic function in mice. The effects of 78c were different between sexes. Our study is the first to investigate the effect of CD38 inhibition in naturally aged animals.
Collapse
Affiliation(s)
- Thais R. Peclat
- Signal Transduction and Molecular Nutrition Laboratory Kogod Aging Center Department of Anesthesiology and Perioperative Medicine Mayo Clinic College of Medicine Rochester Minnesota USA
| | - Katie L. Thompson
- Signal Transduction and Molecular Nutrition Laboratory Kogod Aging Center Department of Anesthesiology and Perioperative Medicine Mayo Clinic College of Medicine Rochester Minnesota USA
| | - Gina M. Warner
- Signal Transduction and Molecular Nutrition Laboratory Kogod Aging Center Department of Anesthesiology and Perioperative Medicine Mayo Clinic College of Medicine Rochester Minnesota USA
| | - Claudia C.S. Chini
- Department of Anesthesiology and Perioperative Medicine Mayo Clinic Jacksonville Florida USA
| | - Mariana G. Tarragó
- Signal Transduction and Molecular Nutrition Laboratory Kogod Aging Center Department of Anesthesiology and Perioperative Medicine Mayo Clinic College of Medicine Rochester Minnesota USA
| | - Delaram Z. Mazdeh
- Signal Transduction and Molecular Nutrition Laboratory Kogod Aging Center Department of Anesthesiology and Perioperative Medicine Mayo Clinic College of Medicine Rochester Minnesota USA
| | | | | | | | | | | | - Eduardo N. Chini
- Signal Transduction and Molecular Nutrition Laboratory Kogod Aging Center Department of Anesthesiology and Perioperative Medicine Mayo Clinic College of Medicine Rochester Minnesota USA
- Department of Anesthesiology and Perioperative Medicine Mayo Clinic Jacksonville Florida USA
| |
Collapse
|
9
|
Mohrin M, Liu J, Zavala‐Solorio J, Bhargava S, Maxwell Trumble J, Brito A, Hu D, Brooks D, Koukos G, Alabdulaaly L, Paw JS, Hake K, Kolumam G, Bouxsein ML, Baron R, Kutskova Y, Freund A. Inhibition of longevity regulator PAPP-A modulates tissue homeostasis via restraint of mesenchymal stromal cells. Aging Cell 2021; 20:e13313. [PMID: 33561324 PMCID: PMC7963332 DOI: 10.1111/acel.13313] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2020] [Revised: 11/08/2020] [Accepted: 12/31/2020] [Indexed: 12/20/2022] Open
Abstract
Pregnancy‐associated plasma protein‐A (PAPP‐A) is a secreted metalloprotease that increases insulin‐like growth factor (IGF) availability by cleaving IGF‐binding proteins. Reduced IGF signaling extends longevity in multiple species, and consistent with this, PAPP‐A deletion extends lifespan and healthspan; however, the mechanism remains unclear. To clarify PAPP‐A’s role, we developed a PAPP‐A neutralizing antibody and treated adult mice with it. Transcriptomic profiling across tissues showed that anti‐PAPP‐A reduced IGF signaling and extracellular matrix (ECM) gene expression system wide. The greatest reduction in IGF signaling occurred in the bone marrow, where we found reduced bone, marrow adiposity, and myelopoiesis. These diverse effects led us to search for unifying mechanisms. We identified mesenchymal stromal cells (MSCs) as the source of PAPP‐A in bone marrow and primary responders to PAPP‐A inhibition. Mice treated with anti‐PAPP‐A had reduced IGF signaling in MSCs and dramatically decreased MSC number. As MSCs are (1) a major source of ECM and the progenitors of ECM‐producing fibroblasts, (2) the originating source of adult bone, (3) regulators of marrow adiposity, and (4) an essential component of the hematopoietic niche, our data suggest that PAPP‐A modulates bone marrow homeostasis by potentiating the number and activity of MSCs. We found that MSC‐like cells are the major source of PAPP‐A in other tissues also, suggesting that reduced MSC‐like cell activity drives the system‐wide reduction in ECM gene expression due to PAPP‐A inhibition. Dysregulated ECM production is associated with aging and drives age‐related diseases, and thus, this may be a mechanism by which PAPP‐A deficiency enhances longevity.
Collapse
Affiliation(s)
- Mary Mohrin
- Calico Life Sciences LLC South San Francisco CA USA
| | - Justin Liu
- Calico Life Sciences LLC South San Francisco CA USA
| | | | | | | | | | - Dorothy Hu
- Harvard School of Dental Medicine Boston MA USA
| | - Daniel Brooks
- Center for Advanced Orthopaedic Studies Beth Israel Deaconess Medical Center Boston MA USA
| | | | | | | | - Kayley Hake
- Calico Life Sciences LLC South San Francisco CA USA
| | | | - Mary L. Bouxsein
- Center for Advanced Orthopaedic Studies Beth Israel Deaconess Medical Center Boston MA USA
- Harvard Medical School Boston MA USA
| | - Roland Baron
- Harvard School of Dental Medicine Boston MA USA
- Harvard Medical School Boston MA USA
| | | | - Adam Freund
- Calico Life Sciences LLC South San Francisco CA USA
| |
Collapse
|
10
|
Fazakerley DJ, Chaudhuri R, Yang P, Maghzal GJ, Thomas KC, Krycer JR, Humphrey SJ, Parker BL, Fisher-Wellman KH, Meoli CC, Hoffman NJ, Diskin C, Burchfield JG, Cowley MJ, Kaplan W, Modrusan Z, Kolumam G, Yang JY, Chen DL, Samocha-Bonet D, Greenfield JR, Hoehn KL, Stocker R, James DE. Mitochondrial CoQ deficiency is a common driver of mitochondrial oxidants and insulin resistance. eLife 2018; 7:32111. [PMID: 29402381 PMCID: PMC5800848 DOI: 10.7554/elife.32111] [Citation(s) in RCA: 75] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2017] [Accepted: 01/02/2018] [Indexed: 12/11/2022] Open
Abstract
Insulin resistance in muscle, adipocytes and liver is a gateway to a number of metabolic diseases. Here, we show a selective deficiency in mitochondrial coenzyme Q (CoQ) in insulin-resistant adipose and muscle tissue. This defect was observed in a range of in vitro insulin resistance models and adipose tissue from insulin-resistant humans and was concomitant with lower expression of mevalonate/CoQ biosynthesis pathway proteins in most models. Pharmacologic or genetic manipulations that decreased mitochondrial CoQ triggered mitochondrial oxidants and insulin resistance while CoQ supplementation in either insulin-resistant cell models or mice restored normal insulin sensitivity. Specifically, lowering of mitochondrial CoQ caused insulin resistance in adipocytes as a result of increased superoxide/hydrogen peroxide production via complex II. These data suggest that mitochondrial CoQ is a proximal driver of mitochondrial oxidants and insulin resistance, and that mechanisms that restore mitochondrial CoQ may be effective therapeutic targets for treating insulin resistance. After we eat, our blood sugar levels increase. To counteract this, the pancreas releases a hormone called insulin. Part of insulin’s effect is to promote the uptake of sugar from the blood into muscle and fat tissue for storage. Under certain conditions, such as obesity, this process can become defective, leading to a condition known as insulin resistance. This condition makes a number of human diseases more likely to develop, including type 2 diabetes. Working out how insulin resistance develops could therefore unveil new treatment strategies for these diseases. Mitochondria – structures that produce most of a cell’s energy supply – appear to play a role in the development of insulin resistance. Mitochondria convert nutrients such as fats and sugars into molecules called ATP that fuel the many processes required for life. However, ATP production can also generate potentially harmful intermediates often referred to as ‘reactive oxygen species’ or ‘oxidants’. Previous studies have suggested that an increase in the amount of oxidants produced in mitochondria can cause insulin resistance. Fazakerley et al. therefore set out to identify the reason for increased oxidants in mitochondria, and did so by analysing the levels of proteins and oxidants found in cells grown in the laboratory, and mouse and human tissue samples. This led them to find that concentrations of a molecule called coenzyme Q (CoQ), an essential component of mitochondria that helps to produce ATP, were lower in mitochondria from insulin-resistant fat and muscle tissue. Further experiments suggested a link between the lower levels of CoQ and the higher levels of oxidants in the mitochondria. Replenishing the mitochondria of the lab-grown cells and insulin-resistant mice with CoQ restored ‘normal’ oxidant levels and prevented the development of insulin resistance. Strategies that aim to increase mitochondria CoQ levels may therefore prevent or reverse insulin resistance. Although CoQ supplements are readily available, swallowing CoQ does not efficiently deliver CoQ to mitochondria in humans, so alternative treatment methods must be found. It is also of interest that statins, common drugs taken by millions of people around the world to lower cholesterol, also lower CoQ and have been reported to increase the risk of developing type 2 diabetes. Further research is therefore needed to investigate whether CoQ might provide the link between statins and type 2 diabetes.
Collapse
Affiliation(s)
- Daniel J Fazakerley
- Charles Perkins Centre, School of Life and Environmental Sciences, University of Sydney, Camperdown, Australia
| | - Rima Chaudhuri
- Charles Perkins Centre, School of Life and Environmental Sciences, University of Sydney, Camperdown, Australia
| | - Pengyi Yang
- School of Mathematics and Statistics, University of Sydney, Camperdown, Australia
| | - Ghassan J Maghzal
- Vascular Biology Division, Victor Chang Cardiac Research Institute, Darlinghurst, Australia
| | - Kristen C Thomas
- Charles Perkins Centre, School of Life and Environmental Sciences, University of Sydney, Camperdown, Australia
| | - James R Krycer
- Charles Perkins Centre, School of Life and Environmental Sciences, University of Sydney, Camperdown, Australia
| | - Sean J Humphrey
- Charles Perkins Centre, School of Life and Environmental Sciences, University of Sydney, Camperdown, Australia
| | - Benjamin L Parker
- Charles Perkins Centre, School of Life and Environmental Sciences, University of Sydney, Camperdown, Australia
| | - Kelsey H Fisher-Wellman
- Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, United States
| | - Christopher C Meoli
- Charles Perkins Centre, School of Life and Environmental Sciences, University of Sydney, Camperdown, Australia
| | - Nolan J Hoffman
- Charles Perkins Centre, School of Life and Environmental Sciences, University of Sydney, Camperdown, Australia
| | - Ciana Diskin
- Charles Perkins Centre, School of Life and Environmental Sciences, University of Sydney, Camperdown, Australia
| | - James G Burchfield
- Charles Perkins Centre, School of Life and Environmental Sciences, University of Sydney, Camperdown, Australia
| | - Mark J Cowley
- The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, Australia
| | - Warren Kaplan
- Peter Wills Bioinformatics Centre, Garvan Institute of Medical Research, Darlinghurst, Australia
| | | | | | - Jean Yh Yang
- School of Mathematics and Statistics, University of Sydney, Camperdown, Australia
| | - Daniel L Chen
- Garvan Institute of Medical Research, Darlinghurst, Australia
| | | | | | - Kyle L Hoehn
- School of Biotechnology and Biomedical Sciences, University of New South Wales, Sydney, Australia
| | - Roland Stocker
- Vascular Biology Division, Victor Chang Cardiac Research Institute, Darlinghurst, Australia.,St Vincent's Clinical School, University of New South Wales, Sydney, Australia
| | - David E James
- Charles Perkins Centre, School of Life and Environmental Sciences, University of Sydney, Camperdown, Australia.,Charles Perkins Centre, Sydney Medical School, University of Sydney, Camperdown NSW, Australia
| |
Collapse
|
11
|
Han X, Ross J, Kolumam G, Pi M, Sonoda J, King G, Quarles LD. Cardiovascular Effects of Renal Distal Tubule Deletion of the FGF Receptor 1 Gene. J Am Soc Nephrol 2017; 29:69-80. [PMID: 28993502 DOI: 10.1681/asn.2017040412] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2017] [Accepted: 08/03/2017] [Indexed: 01/11/2023] Open
Abstract
The bone-derived hormone fibroblast growth factor-23 (FGF-23) activates complexes composed of FGF receptors (FGFRs), including FGFR1, and α-Klotho in the kidney distal tubule (DT), leading to increased sodium retention and hypertension. However, the role of FGFR1 in regulating renal processes linked to hypertension is unclear. Here, we investigated the effects of selective FGFR1 loss in the DT. Conditional knockout (cKO) of FGFR1 in the DT (FGFR1DT-cKO mice) resulted in left ventricular hypertrophy (LVH) and decreased kidney expression of α-Klotho in association with enhanced BP, decreased expression of angiotensin converting enzyme 2, and increased expression of the Na+-K+-2Cl- cotransporter. Notably, recombinant FGF-23 administration similarly decreased the kidney expression of α-Klotho and induced LVH in mice. Pharmacologic activation of FGFR1 with a monoclonal anti-FGFR1 antibody (R1MAb1) normalized BP and significantly attenuated LVH in the Hyp mouse model of excess FGF-23, but did not induce a response in FGFR1DT-cKO mice. The hearts of FGFR1DT-cKO mice showed increased expression of the transient receptor potential cation channel, subfamily C, member 6 (TRPC6), consistent with cardiac effects of soluble Klotho deficiency. Moreover, administration of recombinant soluble Klotho lowered BP in the Hyp mice. Thus, FGFR1 in the DT regulates systemic hemodynamic responses opposite to those predicted by the actions of FGF-23. These cardiovascular effects appear to be mediated by paracrine FGF control of kidney FGFR1 and subsequent regulation of soluble Klotho and TRPC6. FGFR1 in the kidney may provide a new molecular target for treating hypertension.
Collapse
Affiliation(s)
- Xiaobin Han
- Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee
| | - Jed Ross
- Department of Molecular Biology and Biomedical Imaging, Genentech, South San Francisco, California; and
| | - Ganesh Kolumam
- Department of Molecular Biology and Biomedical Imaging, Genentech, South San Francisco, California; and
| | - Min Pi
- Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee
| | - Junichiro Sonoda
- Department of Molecular Biology and Biomedical Imaging, Genentech, South San Francisco, California; and
| | - Gwendalyn King
- Department of Neurobiology, University of Alabama in Birmingham, Birmingham, Alabama
| | - L Darryl Quarles
- Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee;
| |
Collapse
|
12
|
Chen MZ, Chang JC, Zavala-Solorio J, Kates L, Thai M, Ogasawara A, Bai X, Flanagan S, Nunez V, Phamluong K, Ziai J, Newman R, Warming S, Kolumam G, Sonoda J. FGF21 mimetic antibody stimulates UCP1-independent brown fat thermogenesis via FGFR1/βKlotho complex in non-adipocytes. Mol Metab 2017; 6:1454-1467. [PMID: 29107292 PMCID: PMC5681280 DOI: 10.1016/j.molmet.2017.09.003] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/08/2017] [Revised: 09/08/2017] [Accepted: 09/12/2017] [Indexed: 02/06/2023] Open
Abstract
Objective Fibroblast Growth Factor 21 (FGF21) is a potent stimulator of brown fat thermogenesis that improves insulin sensitivity, ameliorates hepatosteatosis, and induces weight loss by engaging the receptor complex comprised of Fibroblast Growth Factor Receptor 1 (FGFR1) and the requisite coreceptor βKlotho. Previously, recombinant antibody proteins that activate the FGFR1/βKlotho complex were proposed to act as an FGF21-mimetic; however, in vivo action of these engineered proteins has not been well studied. Methods We investigated the mechanism by which anti-FGFR1/βKlotho bispecific antibody (bFKB1) stimulates thermogenesis in UCP1-expressing brown adipocytes using genetically engineered mice. Anti-FGFR1 agonist antibody was also used to achieve brown adipose tissue restricted activation in transgenic mice. Results Studies with global Ucp1-deficient mice and adipose-specific Fgfr1 deficient mice demonstrated that bFKB1 acts on targets distal to adipocytes and indirectly stimulates brown adipose thermogenesis in a UCP1-independent manner. Using a newly developed transgenic system, we also show that brown adipose tissue restricted activation of a transgenic FGFR1 expressed under the control of Ucp1 promoter does not stimulate energy expenditure. Finally, consistent with its action as a FGF21 mimetic, bFBK1 suppresses intake of saccharin-containing food and alcohol containing water in mice. Conclusions Collectively, we propose that FGFR1/βKlotho targeted therapy indeed mimics the action of FGF21 in vivo and stimulates UCP1-independent brown fat thermogenesis through receptors outside of adipocytes and likely in the nervous system. Anti-FGFR1/βKlotho bispecific antibody stimulates energy expenditure in Ucp1-deficient mice. Anti-FGFR1/βKlotho bispecific antibody stimulates energy expenditure in adipocyte-selective Fgfr1-deficient mice. Brown adipocyte restricted activation of transgenic FGFR1 does not stimulate energy expenditure. Anti-FGFR1/βKlotho bispecific antibody mimics FGF21, inducing sweet and alcohol aversion.
Collapse
Affiliation(s)
- Mark Z Chen
- Molecular Biology, Genentech Inc., South San Francisco, CA, USA
| | - Joshua C Chang
- Molecular Biology, Genentech Inc., South San Francisco, CA, USA
| | | | - Lance Kates
- Molecular Biology, Genentech Inc., South San Francisco, CA, USA
| | - Minh Thai
- Molecular Biology, Genentech Inc., South San Francisco, CA, USA
| | - Annie Ogasawara
- Biomedical Imaging, Genentech Inc., South San Francisco, CA, USA
| | - Xiaobo Bai
- Molecular Biology, Genentech Inc., South San Francisco, CA, USA
| | - Sean Flanagan
- Pathology, Genentech Inc., South San Francisco, CA, USA
| | - Victor Nunez
- Pathology, Genentech Inc., South San Francisco, CA, USA
| | | | - James Ziai
- Pathology, Genentech Inc., South San Francisco, CA, USA
| | - Robert Newman
- Molecular Biology, Genentech Inc., South San Francisco, CA, USA
| | - Søren Warming
- Molecular Biology, Genentech Inc., South San Francisco, CA, USA
| | - Ganesh Kolumam
- Molecular Biology, Genentech Inc., South San Francisco, CA, USA
| | - Junichiro Sonoda
- Molecular Biology, Genentech Inc., South San Francisco, CA, USA.
| |
Collapse
|
13
|
Kolumam G, Wu X, Lee WP, Hackney JA, Zavala-Solorio J, Gandham V, Danilenko DM, Arora P, Wang X, Ouyang W. IL-22R Ligands IL-20, IL-22, and IL-24 Promote Wound Healing in Diabetic db/db Mice. PLoS One 2017; 12:e0170639. [PMID: 28125663 PMCID: PMC5268431 DOI: 10.1371/journal.pone.0170639] [Citation(s) in RCA: 50] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2015] [Accepted: 11/30/2016] [Indexed: 12/21/2022] Open
Abstract
Diabetic foot ulcers (DFU) are one of the major complications in type II diabetes patients and can result in amputation and morbidity. Although multiple approaches are used clinically to help wound closure, many patients still lack adequate treatment. Here we show that IL-20 subfamily cytokines are upregulated during normal wound healing. While there is a redundant role for each individual cytokine in this subfamily in wound healing, mice deficient in IL-22R, the common receptor chain for IL-20, IL-22, and IL-24, display a significant delay in wound healing. Furthermore, IL-20, IL-22 and IL-24 are all able to promote wound healing in type II diabetic db/db mice. Mechanistically, when compared to other growth factors such as VEGF and PDGF that accelerate wound healing in this model, IL-22 uniquely induced genes involved in reepithelialization, tissue remodeling and innate host defense mechanisms from wounded skin. Interestingly, IL-22 treatment showed superior efficacy compared to PDGF or VEGF in an infectious diabetic wound model. Taken together, our data suggest that IL-20 subfamily cytokines, particularly IL-20, IL-22, and IL-24, might provide therapeutic benefit for patients with DFU.
Collapse
Affiliation(s)
- Ganesh Kolumam
- Department of Biomedical Imaging, Genentech, South San Francisco, California, United States of America
| | - Xiumin Wu
- Department of Immunology, Genentech, South San Francisco, California, United States of America
| | - Wyne P. Lee
- Department of Immunology, Genentech, South San Francisco, California, United States of America
| | - Jason A. Hackney
- Department of Bioinformatics and Computational Biology, Genentech, South San Francisco, California, United States of America
| | - Jose Zavala-Solorio
- Department of Molecular Biology, Genentech, South San Francisco, California, United States of America
| | - Vineela Gandham
- Department of Biomedical Imaging, Genentech, South San Francisco, California, United States of America
| | - Dimitry M. Danilenko
- Department of Safety Assessment Pathology, Genentech, South San Francisco, California, United States of America
| | - Puneet Arora
- Department of Early Clinical Development, Genentech, South San Francisco, California, United States of America
| | - Xiaoting Wang
- Department of Immunology, Genentech, South San Francisco, California, United States of America
| | - Wenjun Ouyang
- Department of Immunology, Genentech, South San Francisco, California, United States of America
| |
Collapse
|
14
|
Baughman JM, Rose CM, Kolumam G, Webster JD, Wilkerson EM, Merrill AE, Rhoads TW, Noubade R, Katavolos P, Lesch J, Stapleton DS, Rabaglia ME, Schueler KL, Asuncion R, Domeyer M, Zavala-Solorio J, Reich M, DeVoss J, Keller MP, Attie AD, Hebert AS, Westphall MS, Coon JJ, Kirkpatrick DS, Dey A. NeuCode Proteomics Reveals Bap1 Regulation of Metabolism. Cell Rep 2016; 16:583-595. [PMID: 27373151 PMCID: PMC5546211 DOI: 10.1016/j.celrep.2016.05.096] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2016] [Revised: 04/14/2016] [Accepted: 05/28/2016] [Indexed: 12/13/2022] Open
Abstract
We introduce neutron-encoded (NeuCode) amino acid labeling of mice as a strategy for multiplexed proteomic analysis in vivo. Using NeuCode, we characterize an inducible knockout mouse model of Bap1, a tumor suppressor and deubiquitinase whose in vivo roles outside of cancer are not well established. NeuCode proteomics revealed altered metabolic pathways following Bap1 deletion, including profound elevation of cholesterol biosynthetic machinery coincident with reduced expression of gluconeogenic and lipid homeostasis proteins in liver. Bap1 loss increased pancreatitis biomarkers and reduced expression of mitochondrial proteins. These alterations accompany a metabolic remodeling with hypoglycemia, hypercholesterolemia, hepatic lipid loss, and acinar cell degeneration. Liver-specific Bap1 null mice present with fully penetrant perinatal lethality, severe hypoglycemia, and hepatic lipid deficiency. This work reveals Bap1 as a metabolic regulator in liver and pancreas, and it establishes NeuCode as a reliable proteomic method for deciphering in vivo biology.
Collapse
Affiliation(s)
- Joshua M Baughman
- Department of Protein Chemistry, Genentech, 1 DNA Way, South San Francisco, CA 94080, USA
| | - Christopher M Rose
- Department of Chemistry, University of Wisconsin-Madison, Madison, WI 53706, USA
| | - Ganesh Kolumam
- Department of Molecular Biology, Genentech, 1 DNA Way, South San Francisco, CA 94080, USA
| | - Joshua D Webster
- Department of Pathology, Genentech, 1 DNA Way, South San Francisco, CA 94080, USA
| | - Emily M Wilkerson
- Department of Chemistry, University of Wisconsin-Madison, Madison, WI 53706, USA
| | - Anna E Merrill
- Department of Chemistry, University of Wisconsin-Madison, Madison, WI 53706, USA
| | - Timothy W Rhoads
- Genome Center of Wisconsin, University of Wisconsin-Madison, Madison, WI 53706, USA
| | - Rajkumar Noubade
- Department of Immunology, Genentech, 1 DNA Way, South San Francisco, CA 94080, USA
| | - Paula Katavolos
- Department of Safety Assessment, Genentech, 1 DNA Way, South San Francisco, CA 94080, USA
| | - Justin Lesch
- Department of Translational Immunology, Genentech, 1 DNA Way, South San Francisco, CA 94080, USA
| | - Donald S Stapleton
- Department of Biochemistry, University of Wisconsin-Madison, Madison, WI 53706, USA
| | - Mary E Rabaglia
- Department of Biochemistry, University of Wisconsin-Madison, Madison, WI 53706, USA
| | - Kathy L Schueler
- Department of Biochemistry, University of Wisconsin-Madison, Madison, WI 53706, USA
| | - Raymond Asuncion
- Department of Transgenic Technology, Genentech, 1 DNA Way, South San Francisco, CA 94080, USA
| | - Melanie Domeyer
- Department of Transgenic Technology, Genentech, 1 DNA Way, South San Francisco, CA 94080, USA
| | - Jose Zavala-Solorio
- Department of Molecular Biology, Genentech, 1 DNA Way, South San Francisco, CA 94080, USA
| | - Michael Reich
- Department of Laboratory Animal Resources, Genentech, 1 DNA Way, South San Francisco, CA 94080, USA
| | - Jason DeVoss
- Department of Translational Immunology, Genentech, 1 DNA Way, South San Francisco, CA 94080, USA
| | - Mark P Keller
- Department of Biochemistry, University of Wisconsin-Madison, Madison, WI 53706, USA
| | - Alan D Attie
- Department of Biochemistry, University of Wisconsin-Madison, Madison, WI 53706, USA
| | - Alexander S Hebert
- Genome Center of Wisconsin, University of Wisconsin-Madison, Madison, WI 53706, USA
| | - Michael S Westphall
- Genome Center of Wisconsin, University of Wisconsin-Madison, Madison, WI 53706, USA
| | - Joshua J Coon
- Department of Chemistry, University of Wisconsin-Madison, Madison, WI 53706, USA; Department of Biomolecular Chemistry, University of Wisconsin-Madison, Madison, WI 53706, USA; Genome Center of Wisconsin, University of Wisconsin-Madison, Madison, WI 53706, USA.
| | - Donald S Kirkpatrick
- Department of Protein Chemistry, Genentech, 1 DNA Way, South San Francisco, CA 94080, USA.
| | - Anwesha Dey
- Department of Discovery Oncology, Genentech, 1 DNA Way, South San Francisco, CA 94080, USA.
| |
Collapse
|
15
|
Wertz IE, Newton K, Seshasayee D, Kusam S, Lam C, Zhang J, Popovych N, Helgason E, Schoeffler A, Jeet S, Ramamoorthi N, Kategaya L, Newman RJ, Horikawa K, Dugger D, Sandoval W, Mukund S, Zindal A, Martin F, Quan C, Tom J, Fairbrother WJ, Townsend M, Warming S, DeVoss J, Liu J, Dueber E, Caplazi P, Lee WP, Goodnow CC, Balazs M, Yu K, Kolumam G, Dixit VM. Erratum: Phosphorylation and linear ubiquitin direct A20 inhibition of inflammation. Nature 2016; 532:402. [DOI: 10.1038/nature16541] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
16
|
Wertz IE, Newton K, Seshasayee D, Kusam S, Lam C, Zhang J, Popovych N, Helgason E, Schoeffler A, Jeet S, Ramamoorthi N, Kategaya L, Newman RJ, Horikawa K, Dugger D, Sandoval W, Mukund S, Zindal A, Martin F, Quan C, Tom J, Fairbrother WJ, Townsend M, Warming S, DeVoss J, Liu J, Dueber E, Caplazi P, Lee WP, Goodnow CC, Balazs M, Yu K, Kolumam G, Dixit VM. Phosphorylation and linear ubiquitin direct A20 inhibition of inflammation. Nature 2015; 528:370-5. [PMID: 26649818 DOI: 10.1038/nature16165] [Citation(s) in RCA: 191] [Impact Index Per Article: 21.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2015] [Accepted: 10/11/2015] [Indexed: 12/26/2022]
Abstract
Inactivation of the TNFAIP3 gene, encoding the A20 protein, is associated with critical inflammatory diseases including multiple sclerosis, rheumatoid arthritis and Crohn's disease. However, the role of A20 in attenuating inflammatory signalling is unclear owing to paradoxical in vitro and in vivo findings. Here we utilize genetically engineered mice bearing mutations in the A20 ovarian tumour (OTU)-type deubiquitinase domain or in the zinc finger-4 (ZnF4) ubiquitin-binding motif to investigate these discrepancies. We find that phosphorylation of A20 promotes cleavage of Lys63-linked polyubiquitin chains by the OTU domain and enhances ZnF4-mediated substrate ubiquitination. Additionally, levels of linear ubiquitination dictate whether A20-deficient cells die in response to tumour necrosis factor. Mechanistically, linear ubiquitin chains preserve the architecture of the TNFR1 signalling complex by blocking A20-mediated disassembly of Lys63-linked polyubiquitin scaffolds. Collectively, our studies reveal molecular mechanisms whereby A20 deubiquitinase activity and ubiquitin binding, linear ubiquitination, and cellular kinases cooperate to regulate inflammation and cell death.
Collapse
Affiliation(s)
- Ingrid E Wertz
- Discovery Oncology, Genentech, South San Francisco, California 94080, USA.,Early Discovery Biochemistry, Genentech, South San Francisco, California 94080, USA
| | - Kim Newton
- Physiological Chemistry, Genentech, South San Francisco, California 94080, USA
| | - Dhaya Seshasayee
- Immunology, Genentech, South San Francisco, California 94080, USA
| | - Saritha Kusam
- Early Discovery Biochemistry, Genentech, South San Francisco, California 94080, USA
| | - Cynthia Lam
- Early Discovery Biochemistry, Genentech, South San Francisco, California 94080, USA
| | - Juan Zhang
- Immunology, Genentech, South San Francisco, California 94080, USA
| | - Nataliya Popovych
- Early Discovery Biochemistry, Genentech, South San Francisco, California 94080, USA
| | - Elizabeth Helgason
- Early Discovery Biochemistry, Genentech, South San Francisco, California 94080, USA
| | - Allyn Schoeffler
- Early Discovery Biochemistry, Genentech, South San Francisco, California 94080, USA
| | - Surinder Jeet
- Immunology, Genentech, South San Francisco, California 94080, USA
| | | | - Lorna Kategaya
- Discovery Oncology, Genentech, South San Francisco, California 94080, USA.,Early Discovery Biochemistry, Genentech, South San Francisco, California 94080, USA
| | - Robert J Newman
- Molecular Biology, Genentech, South San Francisco, California 94080, USA
| | - Keisuke Horikawa
- Department of Cancer Biology and Therapeutics, The John Curtin School of Medical Research, The Australian National University, Canberra, Australian Capital Territory 2601, Australia
| | - Debra Dugger
- Physiological Chemistry, Genentech, South San Francisco, California 94080, USA
| | - Wendy Sandoval
- Protein Chemistry, Genentech, South San Francisco, California 94080, USA
| | - Susmith Mukund
- Structural Biology, Genentech, South San Francisco, California 94080, USA
| | - Anuradha Zindal
- Early Discovery Biochemistry, Genentech, South San Francisco, California 94080, USA
| | - Flavius Martin
- Immunology, Genentech, South San Francisco, California 94080, USA
| | - Clifford Quan
- Early Discovery Biochemistry, Genentech, South San Francisco, California 94080, USA
| | - Jeffrey Tom
- Early Discovery Biochemistry, Genentech, South San Francisco, California 94080, USA
| | - Wayne J Fairbrother
- Early Discovery Biochemistry, Genentech, South San Francisco, California 94080, USA
| | - Michael Townsend
- Immunology, Genentech, South San Francisco, California 94080, USA
| | - Søren Warming
- Molecular Biology, Genentech, South San Francisco, California 94080, USA
| | - Jason DeVoss
- Immunology, Genentech, South San Francisco, California 94080, USA
| | - Jinfeng Liu
- Bioinformatics, Genentech, South San Francisco, California 94080, USA
| | - Erin Dueber
- Early Discovery Biochemistry, Genentech, South San Francisco, California 94080, USA
| | - Patrick Caplazi
- Pathology, Genentech, South San Francisco, California 94080, USA
| | - Wyne P Lee
- Immunology, Genentech, South San Francisco, California 94080, USA
| | - Christopher C Goodnow
- Immunogenomics Laboratory, Immunology Division, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, New South Wales 2010, Sydney, Australia
| | - Mercedesz Balazs
- Immunology, Genentech, South San Francisco, California 94080, USA
| | - Kebing Yu
- Protein Chemistry, Genentech, South San Francisco, California 94080, USA
| | - Ganesh Kolumam
- Molecular Biology, Genentech, South San Francisco, California 94080, USA
| | - Vishva M Dixit
- Physiological Chemistry, Genentech, South San Francisco, California 94080, USA
| |
Collapse
|
17
|
Chaudhuri R, Khoo PS, Tonks K, Junutula JR, Kolumam G, Modrusan Z, Samocha-Bonet D, Meoli CC, Hocking S, Fazakerley DJ, Stöckli J, Hoehn KL, Greenfield JR, Yang JYH, James DE. Cross-species gene expression analysis identifies a novel set of genes implicated in human insulin sensitivity. NPJ Syst Biol Appl 2015; 1:15010. [PMID: 28725461 PMCID: PMC5516867 DOI: 10.1038/npjsba.2015.10] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2014] [Revised: 07/24/2015] [Accepted: 08/24/2015] [Indexed: 12/24/2022] Open
Abstract
OBJECTIVE Insulin resistance (IR) is one of the earliest predictors of type 2 diabetes. However, diagnosis of IR is limited. High fat fed mouse models provide key insights into IR. We hypothesized that early features of IR are associated with persistent changes in gene expression (GE) and endeavored to (a) develop novel methods for improving signal:noise in analysis of human GE using mouse models; (b) identify a GE motif that accurately diagnoses IR in humans; and (c) identify novel biology associated with IR in humans. METHODS We integrated human muscle GE data with longitudinal mouse GE data and developed an unbiased three-level cross-species analysis platform (single gene, gene set, and networks) to generate a gene expression motif (GEM) indicative of IR. A logistic regression classification model validated GEM in three independent human data sets (n=115). RESULTS This GEM of 93 genes substantially improved diagnosis of IR compared with routine clinical measures across multiple independent data sets. Individuals misclassified by GEM possessed other metabolic features raising the possibility that they represent a separate metabolic subclass. The GEM was enriched in pathways previously implicated in insulin action and revealed novel associations between β-catenin and Jak1 and IR. Functional analyses using small molecule inhibitors showed an important role for these proteins in insulin action. CONCLUSIONS This study shows that systems approaches for identifying molecular signatures provides a powerful way to stratify individuals into discrete metabolic groups. Moreover, we speculate that the β-catenin pathway may represent a novel biomarker for IR in humans that warrant future investigation.
Collapse
Affiliation(s)
- Rima Chaudhuri
- Charles Perkins Centre, School of Molecular Bioscience, The University of Sydney, Sydney, NSW, Australia.,Diabetes and Obesity Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
| | - Poh Sim Khoo
- Diabetes and Obesity Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
| | - Katherine Tonks
- Diabetes and Obesity Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.,Department of Endocrinology and Diabetes Centre, St Vincent's Hospital, Sydney, NSW, Australia
| | | | | | - Zora Modrusan
- Genentech Incorporated, South San Francisco, CA, USA
| | - Dorit Samocha-Bonet
- Diabetes and Obesity Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.,Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia
| | - Christopher C Meoli
- Diabetes and Obesity Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
| | - Samantha Hocking
- Department of Endocrinology, Royal North Shore Hospital, Sydney, NSW, Australia.,School of Medicine, The University of Sydney, Sydney, NSW, Australia
| | - Daniel J Fazakerley
- Charles Perkins Centre, School of Molecular Bioscience, The University of Sydney, Sydney, NSW, Australia.,Diabetes and Obesity Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
| | - Jacqueline Stöckli
- Charles Perkins Centre, School of Molecular Bioscience, The University of Sydney, Sydney, NSW, Australia.,Diabetes and Obesity Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
| | - Kyle L Hoehn
- School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW, Australia
| | - Jerry R Greenfield
- Diabetes and Obesity Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.,Department of Endocrinology and Diabetes Centre, St Vincent's Hospital, Sydney, NSW, Australia.,Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia
| | - Jean Yee Hwa Yang
- School of Mathematics and Statistics, University of Sydney, Sydney, NSW, Australia
| | - David E James
- Charles Perkins Centre, School of Molecular Bioscience, The University of Sydney, Sydney, NSW, Australia.,Diabetes and Obesity Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.,School of Medicine, The University of Sydney, Sydney, NSW, Australia
| |
Collapse
|
18
|
Solloway M, Madjidi A, Gu C, Eastham-Anderson J, Clarke H, Kljavin N, Zavala-Solorio J, Kates L, Friedman B, Brauer M, Wang J, Fiehn O, Kolumam G, Stern H, Lowe J, Peterson A, Allan B. Glucagon Couples Hepatic Amino Acid Catabolism to mTOR-Dependent Regulation of α-Cell Mass. Cell Rep 2015; 12:495-510. [DOI: 10.1016/j.celrep.2015.06.034] [Citation(s) in RCA: 95] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2014] [Revised: 03/27/2015] [Accepted: 06/09/2015] [Indexed: 02/08/2023] Open
|
19
|
Kolumam G, Chen MZ, Tong R, Zavala-Solorio J, Kates L, van Bruggen N, Ross J, Wyatt SK, Gandham VD, Carano RAD, Dunshee DR, Wu AL, Haley B, Anderson K, Warming S, Rairdan XY, Lewin-Koh N, Zhang Y, Gutierrez J, Baruch A, Gelzleichter TR, Stevens D, Rajan S, Bainbridge TW, Vernes JM, Meng YG, Ziai J, Soriano RH, Brauer MJ, Chen Y, Stawicki S, Kim HS, Comps-Agrar L, Luis E, Spiess C, Wu Y, Ernst JA, McGuinness OP, Peterson AS, Sonoda J. Sustained Brown Fat Stimulation and Insulin Sensitization by a Humanized Bispecific Antibody Agonist for Fibroblast Growth Factor Receptor 1/βKlotho Complex. EBioMedicine 2015; 2:730-43. [PMID: 26288846 PMCID: PMC4534681 DOI: 10.1016/j.ebiom.2015.05.028] [Citation(s) in RCA: 76] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2015] [Revised: 05/26/2015] [Accepted: 05/27/2015] [Indexed: 11/30/2022] Open
Abstract
Dissipating excess calories as heat through therapeutic stimulation of brown adipose tissues (BAT) has been proposed as a potential treatment for obesity-linked disorders. Here, we describe the generation of a humanized effector-less bispecific antibody that activates fibroblast growth factor receptor (FGFR) 1/βKlotho complex, a common receptor for FGF21 and FGF19. Using this molecule, we show that antibody-mediated activation of FGFR1/βKlotho complex in mice induces sustained energy expenditure in BAT, browning of white adipose tissue, weight loss, and improvements in obesity-associated metabolic derangements including insulin resistance, hyperglycemia, dyslipidemia and hepatosteatosis. In mice and cynomolgus monkeys, FGFR1/βKlotho activation increased serum high-molecular-weight adiponectin, which appears to contribute over time by enhancing the amplitude of the metabolic benefits. At the same time, insulin sensitization by FGFR1/βKlotho activation occurs even before the onset of weight loss in a manner that is independent of adiponectin. Together, selective activation of FGFR1/βKlotho complex with a long acting therapeutic antibody represents an attractive approach for the treatment of type 2 diabetes and other obesity-linked disorders through enhanced energy expenditure, insulin sensitization and induction of high-molecular-weight adiponectin. A humanized bispecific antibody that selectively activates FGFR1/βKlotho complex was generated. Anti-FGFR1/βKlotho agonist antibody induced sustained thermogenesis in brown fat and induced weight loss. Anti-FGFR1/βKlotho agonist antibody improved insulin sensitivity even before the onset of weight loss.
Collapse
Affiliation(s)
- Ganesh Kolumam
- Molecular Biology, Genentech, Inc., South San Francisco, CA 94080, USA
| | - Mark Z Chen
- Molecular Biology, Genentech, Inc., South San Francisco, CA 94080, USA
| | - Raymond Tong
- Protein Chemistry, Genentech, Inc., South San Francisco, CA 94080, USA
| | | | - Lance Kates
- Molecular Biology, Genentech, Inc., South San Francisco, CA 94080, USA
| | | | - Jed Ross
- Biomedical Imaging, Genentech, Inc., South San Francisco, CA 94080, USA
| | - Shelby K Wyatt
- Biomedical Imaging, Genentech, Inc., South San Francisco, CA 94080, USA
| | - Vineela D Gandham
- Biomedical Imaging, Genentech, Inc., South San Francisco, CA 94080, USA
| | | | | | - Ai-Luen Wu
- Molecular Biology, Genentech, Inc., South San Francisco, CA 94080, USA
| | - Benjamin Haley
- Molecular Biology, Genentech, Inc., South San Francisco, CA 94080, USA
| | - Keith Anderson
- Molecular Biology, Genentech, Inc., South San Francisco, CA 94080, USA
| | - Søren Warming
- Molecular Biology, Genentech, Inc., South San Francisco, CA 94080, USA
| | - Xin Y Rairdan
- Transgenic Technology, Genentech, Inc., South San Francisco, CA 94080, USA
| | | | - Yingnan Zhang
- Early Discovery Biochemistry, Genentech, Inc., South San Francisco, CA 94080, USA
| | - Johnny Gutierrez
- ITGR/NTA Pharmacodynamic Biomarkers, Genentech, Inc., South San Francisco, CA 94080, USA
| | - Amos Baruch
- ITGR/NTA Pharmacodynamic Biomarkers, Genentech, Inc., South San Francisco, CA 94080, USA
| | | | - Dale Stevens
- Safety Assessment, Genentech, Inc., South San Francisco, CA 94080, USA
| | - Sharmila Rajan
- Preclinical & Translational Pharmacokinetics, Genentech, Inc., South San Francisco, CA 94080, USA
| | | | - Jean-Michel Vernes
- Biochemical and Cellular Pharmacology, Genentech, Inc., South San Francisco, CA 94080, USA
| | - Y Gloria Meng
- Biochemical and Cellular Pharmacology, Genentech, Inc., South San Francisco, CA 94080, USA
| | - James Ziai
- Pathology, Genentech, Inc., South San Francisco, CA 94080, USA
| | - Robert H Soriano
- Molecular Biology, Genentech, Inc., South San Francisco, CA 94080, USA
| | - Matthew J Brauer
- Bioinformatics and Computational Biology, Genentech, Inc., South San Francisco, CA 94080, USA
| | - Yongmei Chen
- Antibody Engineering, Genentech, Inc., South San Francisco, CA 94080, USA
| | - Scott Stawicki
- Antibody Engineering, Genentech, Inc., South San Francisco, CA 94080, USA
| | - Hok Seon Kim
- Antibody Engineering, Genentech, Inc., South San Francisco, CA 94080, USA
| | - Laëtitia Comps-Agrar
- Biochemical and Cellular Pharmacology, Genentech, Inc., South San Francisco, CA 94080, USA
| | - Elizabeth Luis
- Protein Chemistry, Genentech, Inc., South San Francisco, CA 94080, USA
| | - Christoph Spiess
- Antibody Engineering, Genentech, Inc., South San Francisco, CA 94080, USA
| | - Yan Wu
- Antibody Engineering, Genentech, Inc., South San Francisco, CA 94080, USA
| | - James A Ernst
- Protein Chemistry, Genentech, Inc., South San Francisco, CA 94080, USA
| | - Owen P McGuinness
- Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
| | - Andrew S Peterson
- Molecular Biology, Genentech, Inc., South San Francisco, CA 94080, USA
| | - Junichiro Sonoda
- Molecular Biology, Genentech, Inc., South San Francisco, CA 94080, USA
| |
Collapse
|
20
|
Wang X, Ota N, Manzanillo P, Kates L, Zavala-Solorio J, Eidenschenk C, Zhang J, Lesch J, Lee WP, Ross J, Diehl L, van Bruggen N, Kolumam G, Ouyang W. Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes. Nature 2014; 514:237-41. [PMID: 25119041 DOI: 10.1038/nature13564] [Citation(s) in RCA: 323] [Impact Index Per Article: 32.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2013] [Accepted: 06/06/2014] [Indexed: 01/09/2023]
Abstract
The connection between an altered gut microbiota and metabolic disorders such as obesity, diabetes, and cardiovascular disease is well established. Defects in preserving the integrity of the mucosal barriers can result in systemic endotoxaemia that contributes to chronic low-grade inflammation, which further promotes the development of metabolic syndrome. Interleukin (IL)-22 exerts essential roles in eliciting antimicrobial immunity and maintaining mucosal barrier integrity within the intestine. Here we investigate the connection between IL-22 and metabolic disorders. We find that the induction of IL-22 from innate lymphoid cells and CD4(+) T cells is impaired in obese mice under various immune challenges, especially in the colon during infection with Citrobacter rodentium. While innate lymphoid cell populations are largely intact in obese mice, the upregulation of IL-23, a cytokine upstream of IL-22, is compromised during the infection. Consequently, these mice are susceptible to C. rodentium infection, and both exogenous IL-22 and IL-23 are able to restore the mucosal host defence. Importantly, we further unveil unexpected functions of IL-22 in regulating metabolism. Mice deficient in IL-22 receptor and fed with high-fat diet are prone to developing metabolic disorders. Strikingly, administration of exogenous IL-22 in genetically obese leptin-receptor-deficient (db/db) mice and mice fed with high-fat diet reverses many of the metabolic symptoms, including hyperglycaemia and insulin resistance. IL-22 shows diverse metabolic benefits, as it improves insulin sensitivity, preserves gut mucosal barrier and endocrine functions, decreases endotoxaemia and chronic inflammation, and regulates lipid metabolism in liver and adipose tissues. In summary, we identify the IL-22 pathway as a novel target for therapeutic intervention in metabolic diseases.
Collapse
MESH Headings
- Adipose Tissue, White/drug effects
- Adipose Tissue, White/metabolism
- Animals
- CD4-Positive T-Lymphocytes/immunology
- CD4-Positive T-Lymphocytes/metabolism
- Chronic Disease
- Citrobacter rodentium/drug effects
- Citrobacter rodentium/immunology
- Citrobacter rodentium/physiology
- Colon/drug effects
- Colon/immunology
- Colon/microbiology
- Diabetes Mellitus/immunology
- Diabetes Mellitus/metabolism
- Diabetes Mellitus/pathology
- Diet, High-Fat
- Female
- Hyperglycemia/diet therapy
- Hyperglycemia/drug therapy
- Hyperglycemia/metabolism
- Immunity, Mucosal/drug effects
- Inflammation/drug therapy
- Inflammation/metabolism
- Inflammation/pathology
- Insulin/metabolism
- Insulin Resistance
- Interleukin-23/immunology
- Interleukin-23/metabolism
- Interleukin-23/pharmacology
- Interleukins/immunology
- Interleukins/metabolism
- Interleukins/pharmacology
- Interleukins/therapeutic use
- Lipid Metabolism/drug effects
- Liver/drug effects
- Liver/metabolism
- Male
- Metabolic Diseases/diet therapy
- Metabolic Diseases/drug therapy
- Metabolic Diseases/metabolism
- Mice
- Mice, Inbred C57BL
- Mice, Obese
- Obesity/metabolism
- Receptors, Interleukin/deficiency
- Receptors, Interleukin/metabolism
- Receptors, Leptin/deficiency
- Receptors, Leptin/metabolism
- Interleukin-22
Collapse
Affiliation(s)
- Xiaoting Wang
- 1] Department of Immunology, Genentech, South San Francisco, California 94080, USA [2]
| | - Naruhisa Ota
- 1] Department of Immunology, Genentech, South San Francisco, California 94080, USA [2]
| | - Paolo Manzanillo
- Department of Immunology, Genentech, South San Francisco, California 94080, USA
| | - Lance Kates
- Department of Biomedical Imaging, Genentech, South San Francisco, California 94080, USA
| | - Jose Zavala-Solorio
- Department of Biomedical Imaging, Genentech, South San Francisco, California 94080, USA
| | - Celine Eidenschenk
- Department of Immunology, Genentech, South San Francisco, California 94080, USA
| | - Juan Zhang
- Department of Immunology, Genentech, South San Francisco, California 94080, USA
| | - Justin Lesch
- Department of Immunology, Genentech, South San Francisco, California 94080, USA
| | - Wyne P Lee
- Department of Immunology, Genentech, South San Francisco, California 94080, USA
| | - Jed Ross
- Department of Biomedical Imaging, Genentech, South San Francisco, California 94080, USA
| | - Lauri Diehl
- Department of Pathology, Genentech, South San Francisco, California 94080, USA
| | - Nicholas van Bruggen
- Department of Biomedical Imaging, Genentech, South San Francisco, California 94080, USA
| | - Ganesh Kolumam
- 1] Department of Biomedical Imaging, Genentech, South San Francisco, California 94080, USA [2]
| | - Wenjun Ouyang
- Department of Immunology, Genentech, South San Francisco, California 94080, USA
| |
Collapse
|
21
|
Wang X, Ota N, Manzanillo P, Kates L, Zavala-Solorio J, Eidenschenk C, Zhang J, Lesch J, Lee WP, Ross J, Diehl L, van Bruggen N, Kolumam G, Ouyang W. Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes. Nature 2014. [DOI: 78495111110.1038/nature13564' target='_blank'>'"<>78495111110.1038/nature13564] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [78495111110.1038/nature13564','', 'Ganesh Kolumam')">Reference Citation Analysis] [78495111110.1038/nature13564', 21)">What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/29/2022]
78495111110.1038/nature13564" />
|
22
|
Wu LE, Meoli CC, Mangiafico SP, Fazakerley DJ, Cogger VC, Mohamad M, Pant H, Kang MJ, Powter E, Burchfield JG, Xirouchaki CE, Mikolaizak AS, Stöckli J, Kolumam G, van Bruggen N, Gamble JR, Le Couteur DG, Cooney GJ, Andrikopoulos S, James DE. Systemic VEGF-A neutralization ameliorates diet-induced metabolic dysfunction. Diabetes 2014; 63:2656-67. [PMID: 24696450 DOI: 10.2337/db13-1665] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
The vascular endothelial growth factor (VEGF) family of cytokines are important regulators of angiogenesis that have emerged as important targets for the treatment of obesity. While serum VEGF levels rise during obesity, recent studies using genetic models provide conflicting evidence as to whether VEGF prevents or accelerates metabolic dysfunction during obesity. In the current study, we sought to identify the effects of VEGF-A neutralization on parameters of glucose metabolism and insulin action in a dietary mouse model of obesity. Within only 72 h of administration of the VEGF-A-neutralizing monoclonal antibody B.20-4.1, we observed almost complete reversal of high-fat diet-induced insulin resistance principally due to improved insulin sensitivity in the liver and in adipose tissue. These effects were independent of changes in whole-body adiposity or insulin signaling. These findings show an important and unexpected role for VEGF in liver insulin resistance, opening up a potentially novel therapeutic avenue for obesity-related metabolic disease.
Collapse
Affiliation(s)
- Lindsay E Wu
- Diabetes and Obesity Program, Garvan Institute of Medical Research, Darlinghurst, New South Wales, AustraliaLaboratory for Ageing Research, School of Medical Sciences, UNSW Australia, New South Wales, Australia
| | - Christopher C Meoli
- Diabetes and Obesity Program, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia
| | - Salvatore P Mangiafico
- Department of Medicine (Austin Health), The University of Melbourne, Heidelberg, Victoria, Australia
| | - Daniel J Fazakerley
- Diabetes and Obesity Program, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia
| | - Victoria C Cogger
- Centre for Education and Research on Ageing and ANZAC Medical Research Institute, University of Sydney and Concord Hospital, Concord, New South Wales, Australia
| | - Mashani Mohamad
- Centre for Education and Research on Ageing and ANZAC Medical Research Institute, University of Sydney and Concord Hospital, Concord, New South Wales, AustraliaFaculty of Pharmacy, Universiti Teknologi MARA, Bandar Puncak Alam, Selangor, Malaysia
| | - Himani Pant
- Diabetes and Obesity Program, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia
| | - Myung-Jin Kang
- Laboratory for Ageing Research, School of Medical Sciences, UNSW Australia, New South Wales, Australia
| | - Elizabeth Powter
- Centre for the Endothelium, Vascular Biology Program, Centenary Institute, and The University of Sydney, Sydney, Australia
| | - James G Burchfield
- Diabetes and Obesity Program, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia
| | | | - A Stefanie Mikolaizak
- Falls and Balance Research Group, Neuroscience Research Australia, Sydney, Australia
| | - Jacqueline Stöckli
- Diabetes and Obesity Program, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia
| | - Ganesh Kolumam
- Department of Biomedical Imaging, Genentech Inc., San Francisco, CA
| | | | - Jennifer R Gamble
- Centre for the Endothelium, Vascular Biology Program, Centenary Institute, and The University of Sydney, Sydney, Australia
| | - David G Le Couteur
- Centre for Education and Research on Ageing and ANZAC Medical Research Institute, University of Sydney and Concord Hospital, Concord, New South Wales, Australia
| | - Gregory J Cooney
- Diabetes and Obesity Program, Garvan Institute of Medical Research, Darlinghurst, New South Wales, Australia
| | - Sofianos Andrikopoulos
- Department of Medicine (Austin Health), The University of Melbourne, Heidelberg, Victoria, Australia
| | - David E James
- Diabetes and Obesity Program, Garvan Institute of Medical Research, Darlinghurst, New South Wales, AustraliaCharles Perkins Centre, School of Molecular Bioscience, The University of Sydney, Sydney, Australia
| |
Collapse
|
23
|
Mukund S, Shang Y, Clarke HJ, Madjidi A, Corn JE, Kates L, Kolumam G, Chiang V, Luis E, Murray J, Zhang Y, Hötzel I, Koth CM, Allan BB. Inhibitory mechanism of an allosteric antibody targeting the glucagon receptor. J Biol Chem 2013; 288:36168-78. [PMID: 24189067 PMCID: PMC3861664 DOI: 10.1074/jbc.m113.496984] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
Elevated glucagon levels and increased hepatic glucagon receptor (GCGR) signaling contribute to hyperglycemia in type 2 diabetes. We have identified a monoclonal antibody that inhibits GCGR, a class B G-protein coupled receptor (GPCR), through a unique allosteric mechanism. Receptor inhibition is mediated by the binding of this antibody to two distinct sites that lie outside of the glucagon binding cleft. One site consists of a patch of residues that are surface-exposed on the face of the extracellular domain (ECD) opposite the ligand-binding cleft, whereas the second binding site consists of residues in the αA helix of the ECD. A docking model suggests that the antibody does not occlude the ligand-binding cleft. We solved the crystal structure of GCGR ECD containing a naturally occurring G40S mutation and found a shift in the register of the αA helix that prevents antibody binding. We also found that alterations in the αA helix impact the normal function of GCGR. We present a model for the allosteric inhibition of GCGR by a monoclonal antibody that may form the basis for the development of allosteric modulators for the treatment of diabetes and other class B GPCR-related diseases.
Collapse
|
24
|
Li S, Kievit P, Robertson AK, Kolumam G, Li X, von Wachenfeldt K, Valfridsson C, Bullens S, Messaoudi I, Bader L, Cowan KJ, Kamath A, van Bruggen N, Bunting S, Frendéus B, Grove KL. Targeting oxidized LDL improves insulin sensitivity and immune cell function in obese Rhesus macaques. Mol Metab 2013; 2:256-69. [PMID: 24049738 DOI: 10.1016/j.molmet.2013.06.001] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/04/2013] [Revised: 06/03/2013] [Accepted: 06/05/2013] [Indexed: 12/18/2022] Open
Abstract
Oxidation of LDL (oxLDL) is a crucial step in the development of cardiovascular disease. Treatment with antibodies directed against oxLDL can reduce atherosclerosis in rodent models through unknown mechanisms. We demonstrate that through a novel mechanism of immune complex formation and Fc-γ receptor (FcγR) engagement, antibodies targeting oxLDL (MLDL1278a) are anti-inflammatory on innate immune cells via modulation of Syk, p38 MAPK phosphorylation and NFκB activity. Subsequent administration of MLDL1278a in diet-induced obese (DIO) nonhuman primates (NHP) resulted in a significant decrease in pro-inflammatory cytokines and improved overall immune cell function. Importantly, MLDL1278a treatment improved insulin sensitivity independent of body weight change. This study demonstrates a novel mechanism by which an anti-oxLDL antibody improves immune function and insulin sensitivity independent of internalization of oxLDL. This identifies MLDL1278a as a potential therapy for reducing vascular inflammation in diabetic conditions.
Collapse
Affiliation(s)
- Shijie Li
- Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, United States
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Brauer MJ, Zhuang G, Schmidt M, Yao J, Wu X, Kaminker JS, Jurinka SS, Kolumam G, Chung AS, Jubb A, Modrusan Z, Ozawa T, James CD, Phillips H, Haley B, Tam RNW, Clermont AC, Cheng JH, Yang SX, Swain SM, Chen D, Scherer SJ, Koeppen H, Yeh RF, Yue P, Stephan JP, Hegde P, Ferrara N, Singh M, Bais C. Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies. Clin Cancer Res 2013; 19:3681-92. [PMID: 23685835 DOI: 10.1158/1078-0432.ccr-12-3635] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
PURPOSE The aim of this study was to identify conserved pharmacodynamic and potential predictive biomarkers of response to anti-VEGF therapy using gene expression profiling in preclinical tumor models and in patients. EXPERIMENTAL DESIGN Surrogate markers of VEGF inhibition [VEGF-dependent genes or VEGF-dependent vasculature (VDV)] were identified by profiling gene expression changes induced in response to VEGF blockade in preclinical tumor models and in human biopsies from patients treated with anti-VEGF monoclonal antibodies. The potential value of VDV genes as candidate predictive biomarkers was tested by correlating high or low VDV gene expression levels in pretreatment clinical samples with the subsequent clinical efficacy of bevacizumab (anti-VEGF)-containing therapy. RESULTS We show that VDV genes, including direct and more distal VEGF downstream endothelial targets, enable detection of VEGF signaling inhibition in mouse tumor models and human tumor biopsies. Retrospective analyses of clinical trial data indicate that patients with higher VDV expression in pretreatment tumor samples exhibited improved clinical outcome when treated with bevacizumab-containing therapies. CONCLUSIONS In this work, we identified surrogate markers (VDV genes) for in vivo VEGF signaling in tumors and showed clinical data supporting a correlation between pretreatment VEGF bioactivity and the subsequent efficacy of anti-VEGF therapy. We propose that VDV genes are candidate biomarkers with the potential to aid the selection of novel indications as well as patients likely to respond to anti-VEGF therapy. The data presented here define a diagnostic biomarker hypothesis based on translational research that warrants further evaluation in additional retrospective and prospective trials.
Collapse
|
26
|
Tonks KT, Ng Y, Miller S, Coster ACF, Samocha-Bonet D, Iseli TJ, Xu A, Patrick E, Yang JYH, Junutula JR, Modrusan Z, Kolumam G, Stöckli J, Chisholm DJ, James DE, Greenfield JR. Impaired Akt phosphorylation in insulin-resistant human muscle is accompanied by selective and heterogeneous downstream defects. Diabetologia 2013; 56:875-85. [PMID: 23344726 DOI: 10.1007/s00125-012-2811-y] [Citation(s) in RCA: 64] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/07/2012] [Accepted: 11/29/2012] [Indexed: 01/04/2023]
Abstract
AIMS/HYPOTHESIS Muscle insulin resistance, one of the earliest defects associated with type 2 diabetes, involves changes in the phosphoinositide 3-kinase/Akt network. The relative contribution of obesity vs insulin resistance to perturbations in this pathway is poorly understood. METHODS We used phosphospecific antibodies against targets in the Akt signalling network to study insulin action in muscle from lean, overweight/obese and type 2 diabetic individuals before and during a hyperinsulinaemic-euglycaemic clamp. RESULTS Insulin-stimulated Akt phosphorylation at Thr309 and Ser474 was highly correlated with whole-body insulin sensitivity. In contrast, impaired phosphorylation of Akt substrate of 160 kDa (AS160; also known as TBC1D4) was associated with adiposity, but not insulin sensitivity. Neither insulin sensitivity nor obesity was associated with defective insulin-dependent phosphorylation of forkhead box O (FOXO) transcription factor. In view of the resultant basal hyperinsulinaemia, we predicted that this selective response within the Akt pathway might lead to hyperactivation of those processes that were spared. Indeed, the expression of genes targeted by FOXO was downregulated in insulin-resistant individuals. CONCLUSIONS/INTERPRETATION These results highlight non-linearity in Akt signalling and suggest that: (1) the pathway from Akt to glucose transport is complex; and (2) pathways, particularly FOXO, that are not insulin-resistant, are likely to be hyperactivated in response to hyperinsulinaemia. This facet of Akt signalling may contribute to multiple features of the metabolic syndrome.
Collapse
Affiliation(s)
- K T Tonks
- Diabetes and Obesity Research Program, Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, 2010 NSW, Australia
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Wu AL, Feng B, Chen MZ, Kolumam G, Zavala-Solorio J, Wyatt SK, Gandham VD, Carano RAD, Sonoda J. Antibody-mediated activation of FGFR1 induces FGF23 production and hypophosphatemia. PLoS One 2013; 8:e57322. [PMID: 23451204 PMCID: PMC3579827 DOI: 10.1371/journal.pone.0057322] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2012] [Accepted: 01/21/2013] [Indexed: 11/18/2022] Open
Abstract
The phosphaturic hormone Fibroblast Growth Factor 23 (FGF23) controls phosphate homeostasis by regulating renal expression of sodium-dependent phosphate co-transporters and cytochrome P450 enzymes involved in vitamin D catabolism. Multiple FGF Receptors (FGFRs) can act as receptors for FGF23 when bound by the co-receptor Klotho expressed in the renal tubular epithelium. FGFRs also regulate skeletal FGF23 secretion; ectopic FGFR activation is implicated in genetic conditions associated with FGF23 overproduction and hypophosphatemia. The identity of FGFRs that mediate the activity of FGF23 or that regulate skeletal FGF23 secretion remains ill defined. Here we report that pharmacological activation of FGFR1 with monoclonal anti-FGFR1 antibodies (R1MAb) in adult mice is sufficient to cause an elevation in serum FGF23 and mild hypophosphatemia. In cultured rat calvariae osteoblasts, R1MAb induces FGF23 mRNA expression and FGF23 protein secretion into the culture medium. In a cultured kidney epithelial cell line, R1MAb acts as a functional FGF23 mimetic and activates the FGF23 program. siRNA-mediated Fgfr1 knockdown induced the opposite effects. Taken together, our work reveals the central role of FGFR1 in the regulation of FGF23 production and signal transduction, and has implications in the pathogenesis of FGF23-related hypophosphatemic disorders.
Collapse
Affiliation(s)
- Ai-Luen Wu
- Department of Molecular Biology, Genentech, Inc., South San Francisco, California, United States of America
| | - Bo Feng
- Department of Molecular Biology, Genentech, Inc., South San Francisco, California, United States of America
| | - Mark Z. Chen
- Department of Molecular Biology, Genentech, Inc., South San Francisco, California, United States of America
| | - Ganesh Kolumam
- Biomedical Imaging, Genentech, Inc., South San Francisco, California, United States of America
| | - Jose Zavala-Solorio
- Biomedical Imaging, Genentech, Inc., South San Francisco, California, United States of America
| | - Shelby K. Wyatt
- Biomedical Imaging, Genentech, Inc., South San Francisco, California, United States of America
| | - Vineela D. Gandham
- Biomedical Imaging, Genentech, Inc., South San Francisco, California, United States of America
| | - Richard A. D. Carano
- Biomedical Imaging, Genentech, Inc., South San Francisco, California, United States of America
| | - Junichiro Sonoda
- Department of Molecular Biology, Genentech, Inc., South San Francisco, California, United States of America
- * E-mail:
| |
Collapse
|
28
|
Lipari MT, Li W, Moran P, Kong-Beltran M, Sai T, Lai J, Lin SJ, Kolumam G, Zavala-Solorio J, Izrael-Tomasevic A, Arnott D, Wang J, Peterson AS, Kirchhofer D. Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels. J Biol Chem 2012; 287:43482-91. [PMID: 23135270 PMCID: PMC3527935 DOI: 10.1074/jbc.m112.380618] [Citation(s) in RCA: 65] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023] Open
Abstract
Proprotein convertase subtilisin/kexin 9 (PCSK9) regulates plasma LDL cholesterol levels by regulating the degradation of LDL receptors. Another proprotein convertase, furin, cleaves PCSK9 at Arg218-Gln219 in the surface-exposed “218 loop.” This cleaved form circulates in blood along with the intact form, albeit at lower concentrations. To gain a better understanding of how cleavage affects PCSK9 function, we produced recombinant furin-cleaved PCSK9 using antibody Ab-3D5, which binds the intact but not the cleaved 218 loop. Using Ab-3D5, we also produced highly purified hepsin-cleaved PCSK9. Hepsin cleaves PCSK9 at Arg218-Gln219 more efficiently than furin but also cleaves at Arg215-Phe216. Further analysis by size exclusion chromatography and mass spectrometry indicated that furin and hepsin produced an internal cleavage in the 218 loop without the loss of the N-terminal segment (Ser153–Arg218), which remained attached to the catalytic domain. Both furin- and hepsin-cleaved PCSK9 bound to LDL receptor with only 2-fold reduced affinity compared with intact PCSK9. Moreover, they reduced LDL receptor levels in HepG2 cells and in mouse liver with only moderately lower activity than intact PCSK9, consistent with the binding data. Single injection into mice of furin-cleaved PCSK9 resulted in significantly increased serum cholesterol levels, approaching the increase by intact PCSK9. These findings indicate that circulating furin-cleaved PCSK9 is able to regulate LDL receptor and serum cholesterol levels, although somewhat less efficiently than intact PCSK9. Therapeutic anti-PCSK9 approaches that neutralize both forms should be the most effective in preserving LDL receptors and in lowering plasma LDL cholesterol.
Collapse
Affiliation(s)
- Michael T Lipari
- Department of Early Discovery Biochemistry, Genentech, Inc., South San Francisco, California 94080, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Zhang Y, Zhou L, Kong-Beltran M, Li W, Moran P, Wang J, Quan C, Tom J, Kolumam G, Elliott JM, Skelton NJ, Peterson AS, Kirchhofer D. Calcium-independent inhibition of PCSK9 by affinity-improved variants of the LDL receptor EGF(A) domain. J Mol Biol 2012; 422:685-696. [PMID: 22728257 DOI: 10.1016/j.jmb.2012.06.018] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2012] [Revised: 06/06/2012] [Accepted: 06/11/2012] [Indexed: 11/26/2022]
Abstract
LDL (low-density lipoprotein) receptor (LDLR) binds to its negative regulator proprotein convertase subtilisin/kexin type 9 (PCSK9) through the first EGF (epidermal growth factor-like) domain [EGF(A)]. The isolated EGF(A) domain is a poor antagonist due to its low affinity for PCSK9. To improve binding affinity, we used a phage display approach by randomizing seven PCSK9 contact residues of EGF(A), including the Ca(2+)-coordinating Asp310. The library was panned in Ca(2+)-free solution, and 26 unique clones that bind to PCSK9 were identified. Four selected variants demonstrated improved inhibitory activities in a PCSK9-LDLR competition binding ELISA. The Fc fusion protein of variant EGF66 bound to PCSK9 with a K(d) value of 71 nM versus 935 nM of wild type [EGF(A)-Fc] and showed significantly improved potency in inhibiting LDLR degradation in vitro and in vivo. The five mutations in EGF66 could be modeled in the EGF(A) structure without perturbation of the EGF domain fold, and their contribution to affinity improvement could be rationalized. The most intriguing change was the substitution of the Ca(2+)-coordinating Asp310 by a Lys residue, whose side-chain amine may have functionally replaced Ca(2+). EGF66-Fc and other EGF variants having the Asp310Lys change bound to PCSK9 in a Ca(2+)-independent fashion. The findings indicate that randomization of an important Ca(2+)-chelating residue in conjunction with "selection pressure" applied by Ca(2+)-free phage selection conditions can yield variants with an alternatively stabilized Ca(2+) loop and with increased binding affinities. This approach may provide a new paradigm for the use of diversity libraries to improve affinities of members of the Ca(2+)-binding EGF domain subfamily.
Collapse
Affiliation(s)
- Yingnan Zhang
- Department of Early Discovery Biochemistry, Genentech, Inc., South San Francisco, CA 94080, USA.
| | - Lijuan Zhou
- Department of Early Discovery Biochemistry, Genentech, Inc., South San Francisco, CA 94080, USA
| | - Monica Kong-Beltran
- Department of Molecular Biology, Genentech, Inc., South San Francisco, CA 94080, USA
| | - Wei Li
- Department of Early Discovery Biochemistry, Genentech, Inc., South San Francisco, CA 94080, USA
| | - Paul Moran
- Department of Early Discovery Biochemistry, Genentech, Inc., South San Francisco, CA 94080, USA
| | - Jianyong Wang
- Department of Assay Automation Technology, Genentech, Inc., South San Francisco, CA 94080, USA
| | - Clifford Quan
- Department of Early Discovery Biochemistry, Genentech, Inc., South San Francisco, CA 94080, USA
| | - Jeffrey Tom
- Department of Early Discovery Biochemistry, Genentech, Inc., South San Francisco, CA 94080, USA
| | - Ganesh Kolumam
- Department of Biomedical Imaging, Genentech, Inc., South San Francisco, CA 94080, USA
| | - J Michael Elliott
- Department of Protein Chemistry, Genentech, Inc., South San Francisco, CA 94080, USA
| | - Nicholas J Skelton
- Department of Medicinal Chemistry, Genentech, Inc., South San Francisco, CA 94080, USA
| | - Andrew S Peterson
- Department of Molecular Biology, Genentech, Inc., South San Francisco, CA 94080, USA
| | - Daniel Kirchhofer
- Department of Early Discovery Biochemistry, Genentech, Inc., South San Francisco, CA 94080, USA.
| |
Collapse
|
30
|
Belcik JT, Qi Y, Kaufmann BA, Xie A, Bullens S, Morgan TK, Bagby SP, Kolumam G, Kowalski J, Oyer JA, Bunting S, Lindner JR. Cardiovascular and systemic microvascular effects of anti-vascular endothelial growth factor therapy for cancer. J Am Coll Cardiol 2012; 60:618-25. [PMID: 22703929 DOI: 10.1016/j.jacc.2012.02.053] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/03/2011] [Revised: 02/02/2012] [Accepted: 02/06/2012] [Indexed: 01/01/2023]
Abstract
OBJECTIVES This study sought to evaluate the contribution of microvascular functional rarefaction and changes in vascular mechanical properties to the development of hypertension and secondary ventricular remodeling that occurs with anti-vascular endothelial growth factor (VEGF) therapy. BACKGROUND Hypertension is a common side effect of VEGF inhibitors used in cancer medicine. METHODS Mice were treated for 5 weeks with an anti-murine VEGF-A monoclonal antibody, antibody plus ramipril, or sham treatment. Microvascular blood flow (MBF) and blood volume (MBV) were quantified by contrast-enhanced ultrasound in skeletal muscle, left ventricle (LV), and kidney. Echocardiography and invasive hemodynamics were used to assess ventricular function, dimensions and vascular mechanical properties. RESULTS Ambulatory blood pressure increased gradually over the first 3 weeks of anti-VEGF therapy. Compared with controls, anti-VEGF-treated mice had similar aortic elastic modulus and histological appearance, but a marked increase in arterial elastance, indicating increased afterload, and elevated plasma angiotensin II. Increased afterload in treated mice led to concentric LV remodeling and reduced stroke volume without impaired LV contractility determined by LV peak change in pressure over time (dp/dt) and the end-systolic dimension-pressure relation. Anti-VEGF therapy did not alter MBF or MBV in skeletal muscle, myocardium, or kidney; but did produce cortical mesangial glomerulosclerosis. Ramipril therapy almost entirely prevented the adverse hemodynamic effects, increased afterload, and LV remodeling in anti-VEGF-treated mice. CONCLUSIONS Neither reduced functional microvascular density nor major alterations in arterial mechanical properties are primary causes of hypertension during anti-VEGF therapy. Inhibition of VEGF leads to an afterload mismatch state, increased angiotensin II, and LV remodeling, which are all ameliorated by angiotensin-converting enzyme inhibition.
Collapse
Affiliation(s)
- J Todd Belcik
- Division of Cardiovascular Medicine, Oregon Health & Science University, Portland, Oregon 97239, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Chiang EY, Kolumam G, McCutcheon KM, Young J, Lin Z, Balazs M, Grogan JL. In vivo depletion of lymphotoxin-alpha expressing lymphocytes inhibits xenogeneic graft-versus-host-disease. PLoS One 2012; 7:e33106. [PMID: 22427961 PMCID: PMC3299734 DOI: 10.1371/journal.pone.0033106] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2011] [Accepted: 02/03/2012] [Indexed: 12/23/2022] Open
Abstract
Graft-versus-host disease (GVHD) is a major barrier to successful allogeneic hematopoietic cell transplantation and is largely mediated by activated donor lymphocytes. Lymphotoxin (LT)-α is expressed by subsets of activated T and B cells, and studies in preclinical models demonstrated that targeted depletion of these cells with a mouse anti-LT-α monoclonal antibody (mAb) was efficacious in inhibiting inflammation and autoimmune disease. Here we demonstrate that LT-α is also upregulated on activated human donor lymphocytes in a xenogeneic model of GVHD and targeted depletion of these donor cells ameliorated GVHD. A depleting humanized anti-LT-α mAb, designated MLTA3698A, was generated that specifically binds to LT-α in both the soluble and membrane-bound forms, and elicits antibody-dependent cellular cytotoxicity (ADCC) activity in vitro. Using a human peripheral blood mononuclear cell transplanted SCID (Hu-SCID) mouse model of GVHD, the anti-human LT-α mAb specifically depleted activated LT-expressing human donor T and B cells, resulting in prolonged survival of the mice. A mutation in the Fc region, rendering the mAb incapable of mediating ADCC, abolished all in vitro and in vivo effects. These data support a role for using a depleting anti-LT-α antibody in treating immune diseases such as GVHD and autoimmune diseases.
Collapse
Affiliation(s)
- Eugene Y. Chiang
- Department of Immunology, Genentech Inc., South San Francisco, California, United States of America
| | - Ganesh Kolumam
- Department of Tumor Biology and Angiogenesis, Genentech Inc., South San Francisco, California, United States of America
| | - Krista M. McCutcheon
- Department of Antibody Engineering, Genentech Inc., South San Francisco, California, United States of America
| | - Judy Young
- Department of Assay and Automation Technology, Genentech Inc., South San Francisco, California, United States of America
| | - Zhonghua Lin
- Department of Immunology, Genentech Inc., South San Francisco, California, United States of America
| | - Mercedesz Balazs
- Department of Immunology, Genentech Inc., South San Francisco, California, United States of America
| | - Jane L. Grogan
- Department of Immunology, Genentech Inc., South San Francisco, California, United States of America
| |
Collapse
|
32
|
Wu AL, Kolumam G, Stawicki S, Chen Y, Li J, Zavala-Solorio J, Phamluong K, Feng B, Li L, Marsters S, Kates L, van Bruggen N, Leabman M, Wong A, West D, Stern H, Luis E, Kim HS, Yansura D, Peterson AS, Filvaroff E, Wu Y, Sonoda J. Amelioration of Type 2 Diabetes by Antibody-Mediated Activation of Fibroblast Growth Factor Receptor 1. Sci Transl Med 2011; 3:113ra126. [DOI: 10.1126/scitranslmed.3002669] [Citation(s) in RCA: 140] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
33
|
Thomas S, Kolumam G, Thompson L, Kaja MK. Effects of bystander inflammatory cytokines on CD8 T cell response to future antigenic encounter. (50.33). The Journal of Immunology 2010. [DOI: 10.4049/jimmunol.184.supp.50.33] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Abstract
Inflammatory cytokines produced during infection act on a wide variety of cells-these include infected as well as uninfected professional antigen presenting cells, T and B cells. Very few of these cells bear receptors specific to the pathogen derived peptides and a majority are bystander cells. Some of these bystander- activated lymphocytes may potentially encounter cognate antigen at later phases. Here we asked what would be the effect of bystander activation on CD8 T cells if they encountered cognate antigen later. We tested this by subjecting ovalbumin-specific TCR transgenic CD8 T cells (OT-1) to Lymphocytic choriomeningitis virus (LCMV) induced bystander activation in vivo and then assessing their response to ovalbumin. Our results show that prior bystander activation drastically diminishes their ability to expand following cognate antigenic exposure. Further experiments show that Type I interferons, a set of inflammatory cytokines produced predominantly during the early infection are mainly responsible for this inhibitory effect on bystander cells. Paradoxically the action of Type I interferons on T cells around the time of antigenic exposure has a markedly positive effect on clonal expansion. These observations suggest that the behavior of T cells is drastically different depending upon whether they receive inflammatory signals prior to or during TCR encounter, and warrants further studies on effects of inflammation in relation to the time of TCR engagement.
Collapse
Affiliation(s)
- Sunil Thomas
- 1Immunology, University Of Washington, Seattle, WA
| | | | | | | |
Collapse
|
34
|
Young J, Yu X, Wolslegel K, Nguyen A, Kung C, Chiang E, Kolumam G, Wei N, Wong WL, DeForge L, Townsend MJ, Grogan JL. Lymphotoxin-alphabeta heterotrimers are cleaved by metalloproteinases and contribute to synovitis in rheumatoid arthritis. Cytokine 2010; 51:78-86. [PMID: 20356761 DOI: 10.1016/j.cyto.2010.03.003] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2009] [Revised: 02/06/2010] [Accepted: 03/05/2010] [Indexed: 11/28/2022]
Abstract
Tumor necrosis factor-superfamily (TNF-SF) members, lymphotoxin (LT)-alpha and LTbeta, are proinflammatory cytokines associated with pathology in rheumatoid arthritis. LTalpha3 homotrimers are secreted, whereas LTalpha(1)beta(2) heterotrimers are expressed on the surface of activated lymphocytes. As many TNF-SF members are actively cleaved from cell membranes, we determined whether LTalphabeta heterotrimers are also cleaved, and are biologically active in rheumatoid arthritis (RA) patients. LTalphabeta heterotrimers were detected in culture supernatants from activated human T-helper (Th) 0, Th1, and Th17 cells, together with LTalpha3 and TNFalpha. The heterotimers were actively cleaved from the cell surface by ADAM17 metalloproteinase (MMP) and MMP-8, and cleavage was inhibited by TAPI-1, a TNF-alpha converting enzyme (TACE) inhibitor. Soluble LTalphabeta was detected in serum from both normal donors and RA patients, and was elevated in synovial fluid from RA patients compared to osteoarthritis (OA) patients. Levels of LTalphabeta in RA patient synovial fluid correlated with increased TNFalpha, IL-8, IL-12, IL-1beta, IFN-gamma, and IL-6 cytokines. Moreover, recombinant LTalpha1beta2-induced CXCL1, CXCL2, IL-6, IL-8, VCAM-1, and ICAM-1 from primary synovial fibroblasts isolated from RA patients. Therefore, soluble LTalphabeta in synovial fluid is associated with a proinflammatory cytokine milieu that contributes to synovitis in RA.
Collapse
Affiliation(s)
- Judy Young
- Department of Assay and Automation Technology, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Grogan JL, Chiang E, Yu X, Kolumam G. Targeted depletion of lymphotoxin-alpha-expressing Th1 and Th17 cells inhibits autoimmune disease (48.22). The Journal of Immunology 2009. [DOI: 10.4049/jimmunol.182.supp.48.22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Abstract
Aberrant autoimmune responses are often underpinned by dysregulated and uncontrolled CD4+ T helper (Th) cell subsets Th1 and Th17. We identify surface lymphotoxin-alpha (LTa) as common to Th1 and Th17 cells and employ a novel strategy to target these subsets using a depleting monoclonal antibody directed to surface LTa. A depleting anti-LTa mAb inhibited T cell-mediated models of delayed-type hypersensitivity and experimental autoimmune encephalomyelitis. In collagen-induced arthritis (CIA), preventive and therapeutic administration of anti-LTa; inhibited disease, resulting in immunoablation of T cells expressing IL-17, IFN-g; and TNF-a, whereas a decoy LTbR fusion protein had no effect. A mutation in the Fc tail, rendering the antibody incapable of FcgR binding and ADCC activity, abolished all in vivo effects. Efficacy in CIA was preceded by a loss of rheumatoid-associated cytokines IL-6, IL-1b and TNF-a within joints. These data indicate that depleting Th1 and Th17 with anti-LTa mAb may be beneficial in the treatment of autoimmune disease.
Collapse
Affiliation(s)
| | | | - Xin Yu
- 1Immunology, Genentech, South San Franicsco, CA
| | | |
Collapse
|